Exicure (XCUR) Non-Current Assets (2016 - 2026)
Exicure's (XCUR) quarterly Non-Current Assets came in at $9.2 million in Q1 2026, down 1.62% YoY from $9.4 million in Q1 2025, and down 2.06% on a QoQ basis from $9.4 million in Q4 2025.
Exicure (XCUR) Non-Current Assets (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Non-Current Assets data on file, last reported at $9.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 1.62% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.6 million (up 40.74% YoY) and the FY2025 annual result came in at $9.4 million, up 580.91% from the prior year.
- Non-Current Assets eased to $9.2 million in Q1 2026, from $9.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $13.9 million in Q2 2023 to a low of $1.4 million in Q4 2024.
- A 5-year average of $10.1 million and a median of $9.8 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets sank 85.53% — and 2025, when it jumped 580.91%.
- Tracing XCUR's Non-Current Assets over 5 years: stood at $13.3 million in 2022, then declined by 28.03% to $9.6 million in 2023, then slumped by 85.53% to $1.4 million in 2024, then jumped by 580.91% to $9.4 million in 2025, then retreated by 2.06% to $9.2 million in 2026.
- The last three Non-Current Assets figures came in at $9.2 million (Q1 2026), $9.4 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | 9.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | 9.42 Mn |
| Sep 30, 2025 | 9.83 Mn |
| Jun 30, 2025 | 10.09 Mn |
| Mar 31, 2025 | 9.38 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 8.03 Mn |
| Jun 30, 2024 | 8.61 Mn |
| Mar 31, 2024 | 9.25 Mn |
| Dec 31, 2023 | 9.56 Mn |
| Sep 30, 2023 | 9.86 Mn |
| Jun 30, 2023 | 13.89 Mn |
| Mar 31, 2023 | 12.67 Mn |
| Dec 31, 2022 | 13.28 Mn |
| Sep 30, 2022 | 11.74 Mn |
| Jun 30, 2022 | 12.23 Mn |
| Mar 31, 2022 | 12.71 Mn |
| Dec 31, 2021 | 21.20 Mn |
| Sep 30, 2021 | 13.75 Mn |
| Jun 30, 2021 | 13.82 Mn |